Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MMP14 | P50281 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3145062 | 0.90 | KCNH2 (0.45) | ALDH1A1SMN1; SMN2KCNH2MAPTCYP1A2 | |
| SCHEMBL3151841 | 0.85 | POLB (0.46) | ALDH1A1SMN1; SMN2MAPTCYP1A2GAA | |
| SCHEMBL3148384 | 0.81 | PPIB (0.43) | ALDH1A1KCNH2CYP1A2GAAMAPK1 | |
| SCHEMBL3936872 | 0.80 | MAPT (0.60) | ALDH1A1SMN1; SMN2MAPTCYP1A2GAA | |
| SCHEMBL3155889 | 0.80 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2MAPTCYP1A2GAA | |
| SCHEMBL3149238 | 0.80 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2MAPTCYP1A2GAA | |
| SCHEMBL3033674 | 0.77 | MAPT (0.64) | ALDH1A1SMN1; SMN2KCNH2MAPTCYP1A2 | |
| SCHEMBL3149099 | 0.77 | MAPT (0.46) | ALDH1A1SMN1; SMN2KCNH2MAPTCYP1A2 | |
| SCHEMBL3154611 | 0.76 | TMEM97 (0.55) | ALDH1A1SMN1; SMN2CYP1A2ATML3MBTL1 | |
| SCHEMBL12006709 | 0.75 | POLB (0.52) | ALDH1A1SMN1; SMN2KCNH2MAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1224170-B9 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 2017-11-22 | — | — | EP | disclosed |
| EP-2157081-A1 | Indolinones substituted in six locations, their manufacture and their application as medicine | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2010-02-24 | — | — | EP | disclosed |
| EP-1224170-B1 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-08-12 | — | — | EP | disclosed |
| US-6762180-B1 | Substituted indolines which inhibit receptor tyrosine kinases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-07-13 | — | — | US | disclosed |
| EP-1224170-A1 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | Boehringer Ingelheim Pharma KG (DE) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001027081-A1 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-04-19 | — | — | WO | disclosed |